Literature DB >> 8222394

Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability.

M Moczar1, F Caux, M Bailly, O Berthier, J F Doré.   

Abstract

Glycosaminoglycans were metabolically labeled in subconfluent cultures of highly metastatic 7Gp122 and poorly metastatic IC8 variants and of the low metastatic parental M4Be human melanoma cell line. Proteoglycans were separated by DEAE Trisacryl chromatography from the culture medium, from the heparin extract of the cell layer and from the heparin-extracted cell residue lyzed with detergents. Glycosaminoglycans were released from the proteoglycans by reductive alkaline hydrolysis and heparan sulfate (HS) was detected by deaminative cleavage with nitrous acid. Expressed on cell protein basis, the labeled HS content in the medium and in the cell layer decreased with increasing metastatic ability. The extraction of HS with heparin from the 7Gp122 cells indicated that this variant was enriched in (polypeptide bound) HS non inserted into the plasma membrane, compared with the low metastatic IC8 and M4Be cells. The HS fraction in heparin extract and in the heparin-extracted cell residue exhibited molecular mass heterogeneity on gel permeation chromatography and it contained HS fragments. Scission with nitrous acid followed by molecular sieve chromatography of the degradation products indicated that the tetra- and disaccharide repeats separated by the N-sulfated glucosamine residue were present in about equal amounts and constituted 60% of the HS chains in the IC8 and M4Be cells. HS from 7Gp122, IC8 and M4Be cells did not bind antithrombin III with high affinity but it was capable of binding bFGF in in vitro assay.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222394     DOI: 10.1007/bf00054937

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  41 in total

Review 1.  Syndecan, a regulator of cell behaviour, is lost in malignant transformation.

Authors:  M Jalkanen; K Elenius; P Inki; J Kirjavainen; S Leppä
Journal:  Biochem Soc Trans       Date:  1991-11       Impact factor: 5.407

Review 2.  Proteoglycans: structures and interactions.

Authors:  L Kjellén; U Lindahl
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

3.  Interactions of exogenous heparan sulfate with tumor cells of different metastatic phenotype.

Authors:  J Timar; M Moczar; K Lapis; E Moczar
Journal:  Invasion Metastasis       Date:  1990

4.  Human tumor spontaneous metastasis in immunosuppressed newborn rats. II. Multiple selections of human melanoma metastatic clones and variants.

Authors:  M Bailly; J F Doré
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

5.  Interactions of thrombospondin with sulfated glycolipids and proteoglycans of human melanoma cells.

Authors:  D D Roberts
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

Review 6.  Heparanases and tumor metastasis.

Authors:  M Nakajima; T Irimura; G L Nicolson
Journal:  J Cell Biochem       Date:  1988-02       Impact factor: 4.429

7.  Oligosaccharides generated by an endoglucuronidase are intermediates in the intracellular degradation of heparan sulfate proteoglycans.

Authors:  L Kjellén; H Pertoft; A Oldberg; M Höök
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

8.  Sequence of human syndecan indicates a novel gene family of integral membrane proteoglycans.

Authors:  M Mali; P Jaakkola; A M Arvilommi; M Jalkanen
Journal:  J Biol Chem       Date:  1990-04-25       Impact factor: 5.157

9.  Involvement of phosphatidylinositol and insulin in the coordinate regulation of proteoheparan sulfate metabolism and hepatocyte growth.

Authors:  M Ishihara; N S Fedarko; H E Conrad
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

10.  Location of antithrombin-binding regions in rat skin heparin proteoglycans.

Authors:  K G Jacobsson; U Lindahl; A A Horner
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

View more
  7 in total

1.  CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes.

Authors:  J R Knutson; J Iida; G B Fields; J B McCarthy
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

2.  Role of Proteoglycans in Tumor Progression.

Authors:  József Timár; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

3.  DAL-1/4.1B promotes the uptake of exosomes in lung cancer cells via Heparan Sulfate Proteoglycan 2 (HSPG2).

Authors:  Shuai Zhang; Min Guo; Tingting Guo; Mingyan Yang; Jiaqi Cheng; Chenyang Cui; Jie Kang; Jiajia Wang; Yuanru Nian; Wenjie Ma; Haibin Weng; Haibo Weng
Journal:  Mol Cell Biochem       Date:  2021-10-17       Impact factor: 3.396

4.  Divergent regulation of proteoglycan and glycosaminoglycan free chain expression in human keratinocytes and melanocytes.

Authors:  M Piepkorn; P Hovingh; A Dillberger; A Linker
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995 Jul-Aug       Impact factor: 2.416

5.  Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth.

Authors:  M Wolańska; K Sobolewski; M Drozdzewicz; E Bańkowski
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

6.  Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells.

Authors:  Fuchuan Li; Gerdy B Ten Dam; Sengottuvelan Murugan; Shuhei Yamada; Taishi Hashiguchi; Shuji Mizumoto; Kayoko Oguri; Minoru Okayama; Toin H van Kuppevelt; Kazuyuki Sugahara
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

7.  GPC3 reduces cell proliferation in renal carcinoma cell lines.

Authors:  Marina Curado Valsechi; Ana Beatriz Bortolozo Oliveira; André Luis Giacometti Conceição; Bruna Stuqui; Natalia Maria Candido; Paola Jocelan Scarin Provazzi; Luiza Ferreira de Araújo; Wilson Araújo Silva; Marilia de Freitas Calmon; Paula Rahal
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.